Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eyepoint Pharmaceuticals Inc (NQ: EYPT )

16.95 -0.70 (-3.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,386,877
Open 17.80
Bid (Size) 17.71 (4)
Ask (Size) 17.90 (1)
Prev. Close 17.65
Today's Range 16.51 - 17.95
52wk Range 5.670 - 30.99
Shares Outstanding 34,984,044
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Critical Insights From EyePoint Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
EYPT Stock Earnings: EyePoint Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023
EYPT stock results show that EyePoint Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-24.73%
-24.73%
1 Month
-21.85%
-21.85%
3 Month
-29.32%
-29.32%
6 Month
+150.93%
+150.93%
1 Year
+118.43%
+118.43%

More News

Read More
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
The 3 Most Promising Stocks to Invest in Before They Take Off
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Unveiling 7 Analyst Insights On EyePoint Pharmaceuticals
Via Benzinga
5 Analysts Have This to Say About EyePoint Pharmaceuticals
Via Benzinga
Earnings Scheduled For March 7, 2024
Via Benzinga
A Preview Of EyePoint Pharmaceuticals's Earnings
Via Benzinga
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration
From EyePoint Pharmaceuticals, Inc.
Via GlobeNewswire
$30M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
Via Benzinga
Topics ETFs
$10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
This Tech Stock Is 'Too Expensive,' Cramer Says: 'Wait For A Pullback'
Via Benzinga
Insiders Buying Dave And 2 Other Stocks
Via Benzinga
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
NIO Reports Q3 Results, Joins Hovnanian Enterprises, Signet Jewelers And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
EyePoint Pharmaceuticals, Hut 8 Mining, GitLab, Take-Two Interactive, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Falls Over 1%; EyePoint Pharmaceuticals Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Gold Down Over 2%; US Factory Orders Fall In October
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is EyePoint Pharmaceuticals (EYPT) Stock Up 187% Today?
Via InvestorPlace
Nasdaq Down Over 100 Points; Alaska Air To Acquire Hawaiian Airlines
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.